Ezetimibe/simvastatin more favorably influences lipoprotein/apolipoprotein ratios than atorvastatin monotherapy in patients with type 2 diabetes
Publication
, Journal Article
Guyton, JR; Goldberg, RB; Mazzone, T; Weinstock, RS; Polis, A; Rosenberg, E; Edwards, P; Tershakovec, AM
Published in: CIRCULATION
October 31, 2006
Duke Scholars
Published In
CIRCULATION
ISSN
0009-7322
Publication Date
October 31, 2006
Volume
114
Issue
18
Start / End Page
797 / 797
Location
Chicago, IL
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Guyton, J. R., Goldberg, R. B., Mazzone, T., Weinstock, R. S., Polis, A., Rosenberg, E., … Tershakovec, A. M. (2006). Ezetimibe/simvastatin more favorably influences lipoprotein/apolipoprotein ratios than atorvastatin monotherapy in patients with type 2 diabetes. CIRCULATION, 114(18), 797–797.
Guyton, John R., Ronald B. Goldberg, Theodore Mazzone, Ruth S. Weinstock, Adam Polis, Elizabeth Rosenberg, Patricia Edwards, and Andrew M. Tershakovec. “Ezetimibe/simvastatin more favorably influences lipoprotein/apolipoprotein ratios than atorvastatin monotherapy in patients with type 2 diabetes.” CIRCULATION 114, no. 18 (October 31, 2006): 797–797.
Guyton JR, Goldberg RB, Mazzone T, Weinstock RS, Polis A, Rosenberg E, et al. Ezetimibe/simvastatin more favorably influences lipoprotein/apolipoprotein ratios than atorvastatin monotherapy in patients with type 2 diabetes. CIRCULATION. 2006 Oct 31;114(18):797–797.
Guyton, John R., et al. “Ezetimibe/simvastatin more favorably influences lipoprotein/apolipoprotein ratios than atorvastatin monotherapy in patients with type 2 diabetes.” CIRCULATION, vol. 114, no. 18, LIPPINCOTT WILLIAMS & WILKINS, Oct. 2006, pp. 797–797.
Guyton JR, Goldberg RB, Mazzone T, Weinstock RS, Polis A, Rosenberg E, Edwards P, Tershakovec AM. Ezetimibe/simvastatin more favorably influences lipoprotein/apolipoprotein ratios than atorvastatin monotherapy in patients with type 2 diabetes. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2006 Oct 31;114(18):797–797.
Published In
CIRCULATION
ISSN
0009-7322
Publication Date
October 31, 2006
Volume
114
Issue
18
Start / End Page
797 / 797
Location
Chicago, IL
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology